Protocol Ledger

NCT03955146 · Phase III · TERMINATED

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Interventional Phase III clinical trial protocol NCT03955146 sponsored by Kyntra Bio in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-18 Enrollment: 393 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03955146
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)393 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03955146
Protocol FieldVerified Registry Value
NCT IdentifierNCT03955146
Consolidated Lead SponsorKyntra Bio
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment393 participants (ACTUAL)
Registered Start Date2019-06-18
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI